Strategic Growth

Evexia Lifecare Limited: Company Overview

Evexia Lifecare Limited, established in 1990 and listed on the Bombay Stock Exchange (BSE) (Script Code - 524444) since 1994, has a rich legacy of business diversification. Since 2020, the company has strategically pivoted towards the pharmaceutical sector, focusing on trading pharmaceutical chemicals with prominent companies in South India.

FCCB Issuance for Growth

The Company is making a strategic move to strengthen its position in the pharmaceutical sector by focusing on high-quality labs, skilled teams, advanced products, and globally recognized plants. Raising funds through the issuance of Foreign Currency Convertible Bonds (FCCBs) worth USD 100 million in the financial year 2022-23 is a significant step toward these goals.

Strategic Acquisition

Strategic Acquisition of Vittals Medicare & UAE Group Companies

Strategic Acquisition

The strategic acquisition of Vittals Medicare Private Limited and its 10 group companies at a valuation of INR 451 crore, with Evexia Lifecare acquiring a 51% stake, represents a pivotal development in company's expansion journey. This acquisition not only reinforces Evexia Lifecare’s commitment to growth but also strengthens its position in the healthcare sector, providing access to new markets and opportunities for synergy.

Our network of 11 clinics in the UAE providing a wide range of medical services is a testament to our commitment to delivering comprehensive healthcare solutions. Offering specialties such as Internal Medicine, General Medicine, Obstetrics & Gynaecology, Pediatrics, ENT, Orthopaedics, Ophthalmology, Dermatology & Cosmetology, Gastroenterology, Radiology, and Dietician services reflects your holistic approach to patient care. Serving approximately 700,000 patients annually with satisfactory outcomes establishes organization as a trusted and leading clinical service provider in the UAE and the Middle East.

Vittals Medicare (established in 2011 in India), is a sovereign healthcare management company with a diverse portfolio of healthcare assets in India. Vittals has dynamic background of bringing new and advanced technology in healthcare delivery.

Advanced Radiology Centre & Clinical Laboratories (ARCCL)

Where we have been providing quality medical imaging services and scans in Dubai and the wider UAE community for over 14 years. Our services include General X-ray, CT, MRI (Open, Extremity MSK & Wide bore), 4D Ultrasound, 3D Mammography, Bone Densitometry (BMD), Orthopantomogram (OPG) and Interventional Radiology Procedures.

We utilize an advanced Picture Archiving and Communication System (PACS). PACS is linked to the hospital’s information infrastructure and enables the medical staff to retrieve, review and share imaging studies from locations throughout the facility.

Strategic Acquisition

Our all labs are approved by

Approvals

Stem Cell Research & Manufacturing

Strategic Acquisition

Evexia has also ventured into the cutting-edge field of stem cell research and manufacturing. The company recently acquired a 75% stake in a DiponEd Bio Private Limited and DiponED Research International Private Limited led by Dr. Kaushik Deb, a globally renowned scientist. Despite regulatory challenges in India related to clinical trials, this acquisition positions Evexia to leverage international advancements in stem cell technology. Manufacturing operations are set to commence within two years.

We utilize an advanced Picture Archiving and Communication System (PACS). PACS is linked to the hospital’s information infrastructure and enables the medical staff to retrieve, review and share imaging studies from locations throughout the facility.

Certifications:

Certifications